Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease

Recent studies suggest that plerixafor mobilization and apheresis in patients with sickle cell disease (SCD) is safe and can allow collection of sufficient CD34(+) hematopoietic stem cell (HSC) collection for clinical gene therapy applications. However, the quantities of plerixafor-mobilized CD34(+)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Leonard, Alexis, Sharma, Akshay, Uchida, Naoya, Stroncek, David, Panch, Sandhya R., West, Kamille, Molloy, Eoghan, Hughes, Thomas E., Hauffe, Sara, Taylor, Tiffani, Fitzhugh, Courtney, Hankins, Jane S., Wilson, Megan, Tsai, Shengdar Q., Weiss, Mitchell J., Hsieh, Matthew, Tisdale, John F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Hematopoiesis and Stem Cells
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8114546/
https://ncbi.nlm.nih.gov/pubmed/33956057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004232
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados